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1. Introduction 
The past several decades have given rise to many important discoveries and novel insights 
into the role of astrocytes in normal brain function and disease, firmly establishing concepts 
that describe the dynamic and reciprocal signaling networks between astrocytes, neurons 
and other cell types.  
Brain aging, overt any neurodegenerative state, leads to inflammation, oxidative stress and 
cell death. Neurons are more susceptible to injury than astrocytes, as they have fewer 
antioxidant mechanisms and are therefore prone to excitotoxicity (Swanson et al., 2004). Both 
normally and with aging, astrocytes support neurons by providing antioxidant protection, 
substrates for neuronal metabolism via neurovascular coupling, and glutamate clearance. 
Although astrocytes are generally more resilient than neurons, severe damage also results in 
astrocyte dysfunction, leading to increased neuronal death (Nedergaard & Dirnagl, 2005). 
Therefore, many recent efforts have focused on the astrocyte-neuron interaction and how 
astrocyte function can be improved to enhance neuronal support and survival (Swanson et 
al., 2004). A growing body of data demonstrates that astrocytes play a multifaceted and 
complex role in the response to neuropathologies, including neurodegenerative, as they 
have potential to both enhance neuronal survival and regeneration and contribute to further 
injury (Sofroniew, 2000, 2009; Sofroniew & Vinters, 2010). Because of the diverse nature and 
complex biology of these cells, and the limited number of studies to date, their role in 
neurodegeneration deserves further study. 
It is likely that diminished astrocytes function throughout the neurodegenerative process is 
a prominent determinant of both neuronal survival as well as survival of the entire 
organism (Shibata & Kobayashi, 2008). In this chapter we provide a brief overview of the 
pathophysiological events underlying brain aging, and in neurodegenerative diseases, and 
discusses how these events affect astrocytes response to these chronic neuropathologies, 
such as Alzheimer’s AD and Parkinson´s PD diseases, Amyotrophic Lateral Syndrome 
(ALS), and Multiple Sclerosis (MS).  
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2. Astrocytes function in the brain  
Astrocytes are the most common cell type in mammalian brain. Glial fibrillary acidic protein 
(GFAP) and vimentin (Vim) constitute intermediate filaments (known also as 
nanofilaments) as part of the cytoskeleton in astrocytes. Reactive gliosis is a response of 
astrocytes to a variety of brain insults that is characterized by hypertrophy of the cell bodies 
and processes, altered gene expression, increase in the expression of GFAP, Vim and the 
calcium binding protein S100ǃ (Ridet et al., 1997), and proliferation that may likely occur in 
some neurodegenerative diseases (Sofroniew, 2009; Sofroniew & Vinters, 2010). In contrast, 
because reactive astrocytes are ubiquitous in aged central nervous system (CNS) tissue, they 
are often regarded as uniformly harmful, provoking inflammation, releasing cytotoxins and 
chemokines that serve no purpose but to inhibit axonal regeneration and increase damage. 
The wide range of activities that astrocytes can exhibit in vitro contributes to uncertainty 
over whether these cells exert beneficial or detrimental effects after CNS degeneration. For 
example, potential protective effects could be provided by glutamate uptake and 
neurotrophin release, while potential detrimental effects might be caused by the release of 
inflammatory cytokines and cytotoxic radicals. Little information has been available on the 
roles played by reactive astrocytes in the response to experimental models of 
neurodegenerative diseases in vivo. For instance, aged astrocytes exhibit an elevated content 
of GFAP and of S100ǃ (Barreto et al., 2009; Nichols, 1999). Use of oligonucleotide arrays has 
yielded the first profile of gene expression from the aging brain of mice and evidence that 
aging seems to be associated with an inflammatory response and oxidative stress both in 
neocortex, hippocampus and in cerebellum (Lee et al., 2000; Zeier et al., 2011), with parallels 
to human neurodegenerative disorders. GFAP is also one of the genes that undergoes a 
twofold increase in expression. Thus, the GFAP increases of the aged astrocytes may be the 
result of a response to the inflammatory and oxidative state of the aging brain. Indeed, 
better comprehension of the features that distinguish a normal, “healthy” old brain from a 
brain that is at an early stage of a neurodegenerative disease is a key aspect in developing 
treatments. 
It is interesting to note that one of the characteristics of astrocytes in the aging brain – the 
number of astrocytes – is increased by ~20% (Peinado et al., 1998; Pilegaard & Ladefoged, 
1996; Rozovsky et al., 1998; Salminen et al., 2011). This response has been compared with 
reactive gliosis in response to injured or damaged neurons during aging. However, an 
alternative explanation is that increased number of astrocytes in the aging brain is required 
to provide the same level of neuroprotection that is present in the brain of a young animal. 
One hallmark of the cellular response to brain aging, and in neurodegenerative states, is a 
rapid, dramatic increase in damaging free radicals, including nitric oxide (NO), superoxide, 
and peroxynitrite (Shibata & Kobayashi, 2008). On the other hand, astrocytes produce the 
beneficial antioxidants glutathione, superoxide dismutases (SODs 1, 2 and 3), and ascorbate 
(Figure 1, Anderson & Swanson, 2000; Dringen, 2000; Dringen et al., 2000; Lindenau et al., 
2000; Sims et al., 2004). Interestingly, neurons cocultured with astrocyte exhibit higher levels 
of glutathione compared with neurons cultured alone (Giordano et al., 2009), suggesting that 
astrocytes provide additional antioxidant defense to neurons (Slemmer et al., 2008). 
Similarly, astrocytes upregulate HO-1 (heme-oxygenase 1, Figure 2), a 32 kDa stress protein 
that degrades heme to biliverdin, free iron and carbon monoxide. Although the 
upregulation of this enzyme has been previously reported to confer neuroprotection 
following various brain insults (Beschorner et al., 2000; Chen et al., 2000; Espada et al., 2010; 
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Fig. 1. Mechanisms of astrocyte support of neurons in the normal brain. Antioxidant defence 
includes release of glutathione and ascorbate. Regulation of extracellular levels of ions and 
neurotransmitters, especially K+ and glutamate, strongly influence neuronal excitability. 
Elevated extracellular K+ triggers astrocyte glycolysis and enhances lactate and pyruvate 
release which support neuronal metabolism. Sodium dependent glutamate uptake by 
astrocytes activates the Na+/K+ ATPase, stimulating glycolytic activity and production of 
lactate. Astrocytes and neurons are also coupled by the glutamate-glutamine cycle. 
Astrocytes take up glutamate, convert it to glutamine, release glutamine to the extracellular 
space where it is taken up by neurons and used to synthesize glutamate to replenishment 
the neurotransmitter pool. Any deregulation of these mechanisms, as a common situation in 
some neurodegenerative diseases, will likely influence neuronal survival 
 
                  HO1                                   NeuN                                  Merge 
 
Fig. 2. Astrocytic HO-1 expression in corpus callosum. Immunostaining for HO-1 and NeuN 
(neuronal marker) was carried out in free floating brain sections of 3 months-old naïve male 
mice. Morphologically, HO-1 is expressed in shaped-like astrocytes, and does not seem to be 
expressed by neurons. Scale bar, 50 µm 
www.intechopen.com
 
Neurodegenerative Diseases – Processes, Prevention, Protection and Monitoring 
 
260 
Imuta et al., 2007; Ku et al., 2006; Le et al., 1999; Takeda et al., 2000), its overproduction in 
astrocytes may contribute to iron overload and mitochondrial insufficiency, characteristic of 
some neurodegenerative disorders (Fernandez-Checa et al., 2010; Serviddio et al., 2011). HO-
1 is expressed by approximately 86% (Schipper et al., 1995) and 77.1% (Schipper et al., 1998) 
of GFAP-positive astrocytes in AD and PD, respectively, suggesting a possible role in the 
pathogenesis of these neurodegenerative diseases.  
Control of energy metabolism is also controlled by astrocytes in the CNS. When astrocytes 
take up extracellular glutamate as a result of neuronal activity, the Na+/ K+-ATPase and 
AMPA signaling trigger astrocyte uptake of glucose from the blood, as astrocytic endfeet 
contact capillaries (Caesar et al., 2008; Magistretti, 2006). The glucose is then made into 
lactate, a substrate for neuronal energy, to further “fuel” active neurons (Magistretti & 
Pellerin, 1999; Figure 1). As mentioned above, astrocytes produce glutathione. In addition to 
its antioxidant properties, glutathione is the enzyme needed for the conversion of 
methylglyoxal, a toxic by-product of metabolism, into D-lactate by glyoxalase 1 (Cliffe & 
Waley, 1961). Although the role of astrocyte metabolism is relatively well-established in 
normal tissues, the role of astrocyte metabolism maintenance with aging and in 
neurodegenerative diseases is less clear (Bartnik-Olson et al., 2010; Bentzer et al., 2000; Floyd 
& Lyeth, 2007).  
Astrocytes are also key players in the production and regulation of neurotransmitters, 
antioxidant production, potassium uptake, energy metabolism and neurovascular coupling 
in the CNS. Notably, astrocytes make glutamine, the precursor for the neurotransmitters 
glutamate and GABA, from glucose (Zou et al., 2010). In addition to providing the 
precursors for neurotransmitters, one important role of astrocytes in the normal brain is to 
take up glutamate using the glutamate transporters GLAST and GLT-1 (Anderson & 
Swanson, 2000; Romera et al., 2004; Schousboe & Waagepetersen, 2006), as excess glutamate 
leads to cell death via excitotoxicity (Tilleux & Hermans, 2007).  
Astrocytes regulate neuronal activation by extracellular potassium uptake, and proper 
maintenance of ion gradients, such as potassium, as an important mechanism for regulating 
cell volume in both normal and pathological conditions (Jayakumar & Norenberg, 2010; 
Lambert & Oberwinkler, 2005; Lang et al., 1998; Obara et al., 2008). Indeed, astrocytes 
upregulate glucose transporters in order to provide energy to dying neuronal cells (Floyd & 
Lyeth, 2007; Scafidi et al., 2009; Yi & Hazell, 2006,) suggesting that astrocytes are necessary 
for improvement in chronic neurodegenerative diseases energy metabolism. In summary, 
astrocytes are important producers of antioxidants in the normal CNS, and astrocytic 
production of these molecules after brain injury may enhance neuronal survival and protect 
astrocyte function. 
Astrocytes are critical in the development and/or maintenance of blood-brain barrier 
characteristics (Gordon et al., 2007; Koehler et al., 2009). Astrocytes are arranged in non-
overlapping spatial domains (Bushong et al., 2002; Halassa et al., 2007), but coupled to each 
other in a syncytial network (Haydon & Carmignoto, 2006). Since one astrocyte maintains 
contacts with approximately 160,000 synapses (Bushong et al., 2002), this cell population is 
well positioned to integrate neuronal activity and link neuronal activity to the vascular 
network (Ransom et al., 2003).  
Astrocytes terminal processes are also known as “endfeet” cover 99% of the abluminal 
vascular surface of capillaries, intracerebral arterioles, and venules (Simard et al., 2003). The 
extent of contact between endfeet and penetrating and pial arterioles remains unclear. Pial 
arterioles and arteries lying free in the subarachnoid space are not covered (Jones, 1970). 
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Nevertheless, much of the pial circulation is in contact with the glia-limitans, a de-facto 
extension of astrocytic processes (Kontos et al., 1971; Xu et al., 2004). This domain 
organization has been proposed as being the key linking element of the neuronal–
(astrocyte)–vascular unit (Volterra & Meldolesi, 2005). For example, working with 
neocortical slices, Zonta et al. (Zonta et al., 2003) demonstrated that electrical stimulation of 
neuronal processes raises intracellular Ca2+ levels in astrocytic endfeet and leads to a slowly 
developing dilatation of local intracerebral arterioles. Additionally, electrical stimulation of 
individual astrocytes had the same effect. Since this initial report, several investigators 
observed a vascular response in conjunction with an elevation of intracellular Ca2+ levels in 
astrocytic endfeet. However, these studies reported inconsistent vascular responses ranging 
from vasorelaxation to vasodilatation or the combination of both (Gordon et al., 2007; 
Iadecola & Nedergaard, 2007). Mediators implicated in this mechanism are vasoactive 
metabolites of the cyclooxygenase or cytochrome P450 ω-hydroxylase pathways. All of these 
studies were performed in brain slices in which the vessels are lacking in intraluminal 
pressure. This might account for disparate results. In vivo analysis with two-photon laser 
scanning microscopy revealed that increases of astrocytic Ca2+ by photolysis of caged Ca2+ 
evoked a vasodilatation of cortical arterioles (Takano et al., 2006). This interaction between 
the vessel and the endfeet appeared to be mediated by metabolites of the COX-1 pathway, 
because inhibitors of nitric oxide synthetase (NOS), COX-2, p450 epoxygenases, and 
adenosine receptor antagonists had no effect. These and other studies strongly implicate a 
role for astrocytes in cerebral blood flow regulation during neuronal activation (Haydon & 
Carmignoto, 2006).  
It is important to point that some, if not all, of these astrocytic functions may likely be 
altered or reduced in neurodegenerative states (Rossi & Volterra, 2009). The role of 
astrocytes in various neurodegenerative diseases will briefly be discussed more thoroughly 
below, specifically looking at their involvement during the pathologic processes of 
Alzheimer´s and Parkinson diseases, Amyotrophic Lateral Syndrome (ALS) and Multiple 
Sclerosis. 
3. Astrocytes dysfunction in neurodegenerative diseases 
Neurodegenerative diseases represent a heterogeneous group of disorders affecting the 
nervous system. In most instances, they affect adults, their causes are unknown, and 
progression is relentless. Some are genetic, but most are sporadic. They involve all parts of 
the nervous system, although the cerebral cortex and the basal ganglia are the most frequent 
loci of pathology. The historical classification of neurodegenerative diseases, based on 
clinical and pathological characteristics, is imperfect. New classifications are rather based on 
molecular determinants. Contrary to common belief, it is now recognized that 
neurodegenerative disorders are multisystemic, even if specific neuronal pathways are more 
affected than others. The death of astrocytes and specific types of neurons in 
neurodegenerative diseases is provoked, not by a single pathogenic factor, but rather by a 
cascade of multiple deleterious molecular and cellular events as described earlier. 
3.1 Oxidative stress and neurodegeneration 
Mitochondria are central neuronal organelles that play a vital role in neuronal life and 
death. Both mitochondrial dysfunction and proper function are essential components in 
neurodegeneration. Further elucidation of the mechanisms of interaction between 
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mitochondria and neuronal death will allow better description of the pathogenesis of 
neurodegenerative diseases and provide potential targets for therapeutic intervention. 
One of the hallmarks of various neurodegenerative and neuroinflammatory disorders is 
oxidative stress-induced CNS damage. Similarly, the natural aging process per se is 
associated with increased oxidative stress (Figure 3). Such oxidative stress can damage 
lipids, proteins and nucleic acids of cells and power-house mitochondria causing cell death 
in assorted cell types including astrocytes and neurons. However, astrocytes having high 
levels of anti-oxidant enzymes (glutathione peroxidase, catalase, glutathione reductase, and 
superoxide dismutase) and antioxidants (glutathione and ascorbic acid) try to absorb 
reactive oxygen species (O2 =, O2 −, and OH.) and reactive nitrogen species (NO, ONOO−), 
maintain redox homeostasis and defend the insulted CNS (Chen & Swanson, 2003; Dringen 
& Hirrlinger, 2003; Wilson, 1997). In addition, astrocytes also scavenge detrimental  
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Fig. 3. Increased oxidative stress production in the normal aged brain. 3- or 18-months naïve 
old male mice were sacrificed and 40 µm brain sections were stained for  
4-Hydroxynonenal (4-HNE), a marker of lipid peroxidation. Mean Fluorescence intensity 
assessed by ImageJ program showed that aged animals, overt any pathological condition, 
had an increased expression of 4-HNE in cortical layers II-III, compared to young mice.  
3 sections/animal for 4 animals were analyzed in each condition. Data are represented as 
Means ± SEM. Scale bar, 100 µm 
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molecules such as glutamate, produced during synaptic transmission through neurons 
(Hertz & Zielke, 2004). This is, perhaps, the most common astrocytic dysfunction that likely 
occurs in some neurodegenerative states.  
Astrocytes react to various neurodegenerative insults rapidly, leading to vigorous 
astrogliosis. This reactive gliosis is associated with alteration in morphology and structure of 
activated astrocytes along with its functional characteristics (Eddleston & Mucke, 1993). The 
astrocytic processes construct a bushy network surrounding the injury site, thus secluding 
the affected part from the rest of the CNS area. Subsequently, astrogliosis has been 
implicated in the pathogenesis of a variety of chronic neurodegenerative diseases, including 
Alzheimer’s disease (AD), Parkinson’s disease, Amyotrophic Lateral Syndrome (ALS ), 
acute traumatic brain injury, stroke, and neuroinflammatory brain diseases (Axelsson et al., 
2011; Ciesielska et al., 2009; Garcia-Matas et al., 2010; Heales et al., 2004; Li et al., 2011; 
Simpson et al., 2010; Sofroniew, 2000).  
3.2 Alzheimer´s disease  
AD is characterized clinically by cognitive loss in two or more domains, including memory, 
language, calculations, orientation and judgment; the loss must be of sufficient severity to 
cause social or occupational disability. These clinical features are the result of neuronal 
death and dysfunction in the cerebral cortex, entorhinal area, hippocampus, ventral striatum 
and basal forebrain, eventually resulting in severe dementia. Pathologically, the two hallmark 
findings of the disorder are neurofibrillary tangles and amyloid plaques (Veerhuis, 2011).  
Senile plaques, a pathologic hallmark of Alzheimer’s disease, are associated with GFAP-
positive activated astrocytes (Nagele et al., 2004). It is reported that in various 
neuropathological states, the increased GFAP expression corresponds to the severity of 
astroglial activation (Axelsson et al., 2011; Kashon et al., 2004; Notturno et al., 2009; Pelinka et 
al., 2004; Simpson et al., 2010; Toft-Hansen et al., 2011). 
Concerning astrocytes, recent findings suggest that they play a role in the clearance of the 
Aǃ- peptide and thus in preventing plaque formation (Li et al., 2011). Similarly, this peptide 
decreases glutamate uptake in cultured astrocytes, thus increasing oxidative stress and and 
activation of mitogen-activated protein kinase cascades (Agostinho et al., 2010; Matos et al., 
2008). High levels of pro-inflammatory cytokines such as interleukin 1ǃ, interleukin 6 and 
TNFǂ, mostly produced by reactive astrocytes, are detected in the brain of AD subjects, so 
the consequences of this phenomenon are unclear, also because pro-inflammatory cytokines 
have varied effects depending on the biological context (Veerhuis, 2011). 
A previous study indicated that activated astrocytes were closely associated with amyloid 
plaques in the molecular layer of the cerebral cortex (Wisniewski & Wegiel, 1991). 
Astrocytes might be activated by human amyloid-ǃ (Aǃ) (DeWitt et al., 1998), indicating a 
correlation between this protein and subsequent alterations in astrocyte function. Astrocytes 
also accumulate neuron-derived amyloid material resulting from local neurodegeneration. 
Once substantial accumulation of this debris occurs, the astrocytes themselves might 
undergo cell death, resulting in the formation of GFAP+ amyloid plaques (Nagele et al., 
2004). In vitro analyses also indicate that treatment of astrocytes with Aǃ results in an 
increase in calcium-wave signaling between these cells (Haughey & Mattson, 2003). In cells 
expressing the familial AD presenilin 1 (PSEN1) mutation, calcium oscillations in astrocytes 
were found to occur at lower ATP and glutamate concentrations than in wild-type 
astrocytes (Johnston et al., 2006). These data support a model in which calcium signaling 
between astrocytes is altered by the disease process, which might, in ways that are not fully 
understood, contribute to dysfunction or death of neurons. 
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Either prooxidant agents or amyloid beta peptide did not cause deleterious effects in the 
astrocytes, but the combined treatment let to oxidative stress and apoptosis in vitro and 
inflammation and degenerative traits in vivo. Therefore, a reduced oxidative stress defense 
capacity in frail aged astrocytes may contribute to neuron death by failure of astrocyte 
support. To preserve astrocyte function and reduce oxidative stress in old age is a new goal 
against AD (Aliev et al., 2009a; Aliev et al., 2009b; Garcia-Matas et al., 2010).  
3.3 Parkinson´s disease 
PD is the second most prevalent neurodegenerative disease, after AD. PD is estimated to 
affect about 1 million Americans, or about 1% of the population over 60 years of age. PD is 
caused by the disruption of dopaminergic neurotransmission in the basal ganglia. On 
pathological examination, the numbers of dopaminergic neurons in the substantia nigra are 
markedly reduced, and Lewy bodies (cytoplasmic inclusions) are present in the residual 
dopaminergic neurons (Nutt & Wooten, 2005). The focus has always been on the loss of 
these dopamanergic neurons and subsequent depletion of dopamine, but a role for non-
neuronal cells in producing neuropathological or neuroprotective functions in PD is 
becoming increasingly recognized.  
The studies that have been carried out to date appear to support a neuroprotective role for 
astrocytes in PD. From pathological examinations, an increase in the number of astrocytes as 
well as in GFAP expression is observed in PD, (Ciesielska et al., 2009; Muramatsu et al., 
2003), as with other neurodegenerative disorders. The pathological evidence indirectly 
indicates that antioxidant pathways might contribute to this neuroprotective effect, because 
in control brains the density of glutathione-peroxidase-positive cells was higher in the 
vicinity of the dopaminergic cell groups known to be resistant to the pathological process of 
PD. The increase in glutathione-peroxidase-containing cells was inversely correlated with 
the severity of dopaminergic cell loss in the respective cell groups in patients with PD. The 
quantity of glutathione-peroxidase-containing cells, therefore, might be critical for a 
protective effect against oxidative stress (Damier et al., 1993). Conversely, the presence of 
synuclein-positive astrocytes in pathological samples has been shown to correlate with 
nigral neuronal cell death (Wakabayashi et al., 2000).  
Nitric oxide production and glutathione depletion also appear as consistent features in 
human PD. The release of glutathione represents another pathway by which astrocytes 
might be neuroprotective in PD models. Glutathione production appears to be increased by 
exposure of astrocytes to nitric oxide, and the increase in glutathione release by astrocytes 
might increase its availability to neurons, thereby making them less susceptible to reactive 
nitrogen species. This pattern is consistent with the data in PD patients, in whom 
glutathione-containing cells are in regions with preserved dopaminergic neurons (Heales et 
al., 2004).  
Evidence regarding regulation of glutamate transporter expression and function in PD has 
been somewhat mixed, with downregulation of glutamate transporters being reported in some 
studies and upregulation being reported in others. The differences in these studies might be 
related to the methods by which the lesions were induced (Maragakis & Rothstein, 2004). 
3.4 Amyotrophic Lateral Syndrome (ALS) 
Amyotrophic Lateral Syndrome is an inexorably progressive motor neuron disease, in 
which both the upper motor neurons and the lower motor neurons degenerate leading to 
www.intechopen.com
 
Role of Astrocytes in Neurodegenerative Diseases 
 
265 
muscle atrophy. Patients eventually experience respiratory failure, usually within three to 
five years from diagnosis. However, the onset of ALS may be subtle and early symptoms are 
frequently overlooked.  
Common to familial and sporadic ALS is the loss of the astrocyte glutamate transporter 
EAAT2. Studies of the EAAT2 transporter in tissue from individuals with sporadic ALS 
showed a marked loss of up to 95% of astroglial EAAT2 protein expression and activity in 
affected areas of the CNS (Bristol & Rothstein, 1996). A clue to a possible mechanism for 
EAAT2 reduction or dysfunction was provided by the finding of aberrant EAAT2 RNA 
species, which has been implicated in multiple neurodegenerative diseases. The production 
of truncated EAAT2 protein results in reduced function, and the retention of normal EAAT2 
protein within the cytoplasm (Lin et al., 1998). The significance of these aberrant EAAT2 
RNA species continues to be debated, however, as they have also been found in some 
normal controls (Flowers et al., 2001; Meyer et al., 1999).  
In both human tissue and transgenic models of ALS, there is abundant evidence that 
astroglial abnormalities and physiological dysfunction precede clinical disease. These 
changes include reactive astrocytosis that can be seen many months before motor neuron 
degeneration (G85R) (Bruijn et al., 1997), and loss of glutamate transport and GLT1 protein 
expression before the onset of clinical disease or overt motor neuron degeneration 
(Howland et al., 2002). Similarly, increased astrocytes activation and expression of 
immune/inflammatory markers are hallmark of this pathology (Chiu et al., 2008; Chiu et al., 
2009). Is the reduction in GLT1 protein in astrocytes significant? Guo and colleagues 
addressed this question by overexpressing the EAAT2 protein in astrocytes in the mSOD1 
mouse model, and demonstrated an increase in motor neuron survival and a delay in 
disease onset; similar outcomes are seen with drugs that increase GLT1 expression (Guo et 
al., 2003). This evidence indicates that EAAT2 expressed in astrocytes - and probably also 
glutamate- influences the timing of disease onset and motor neuron survival (Guo et al., 
2003). Other changes associated with ALS include increased expression of various proteins 
in astrocytes, including inducible nitric oxide synthase (iNOS), the copper chaperone CCS, 
and metallothioneins. Pathologically, early cytosolic proteinaceous aggregates have been 
found in spinal cord astrocytes from the entire mSOD1 mouse lines examined to date (Patel 
& Maragakis, 2002).  
3.5 Multiple Sclerosis 
Multiple Sclerosis is a chronic inflammatory demyelinating disease of the central nervous 
system in which glial cells play a prominent role. In murine experimental autoimmune 
encephalomyelitis (EAE), an established animal model of multiple sclerosis, astrocyte 
hypertrophy coincided with manifestation of axonal damage (Wang et al., 2005). Astrocytes 
in multiple sclerosis plaques produce IL-6 (Okuda et al., 1998), lack ǃ-2 adrenergic receptors, 
and potentially serve as antigen-presenting cells (Zeinstra et al., 2000b), thus facilitating T-
cell invasion and activation. Repeated exposure of these astrocytes to inflammatory 
cytokines triggers unregulated inflammatory responses and increased noradrenalin levels, 
leading to focal areas of myelin and axonal damage (De Keyser et al., 1999; Zeinstra et al., 
2000a).  
Concerning the immune system, class II MHC expressing astrocytes have been shown to 
process and present antigens and activate both naïve and memory T cells (Nikcevich et al., 
1997; Soos et al., 1998). In contrast, other investigators have shown that class II MHC 
expressing astrocytes are not capable of stimulating T-cell proliferation and instead induce 
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apoptosis or down-regulation of T cells (Matsumoto et al., 1992; Weber et al., 1994). Such a 
response may be beneficial for astrocyte suppression of CNS autoimmunity like in multiple 
sclerosis. 
4. Conclusions 
Astrocytes play a critical role in normal function of the mammalian nervous system. 
Astrocytes regulate K+ buffering, glutamate clearance, brain antioxidant defense, close 
metabolic coupling with neurons, and modulation of neuronal excitability. In numerous 
pathological states, such as AD, PD, ALS and ME, astrocytes are involved in both 
exacerbation of damage and neuroprotective mechanisms. As discussed in this chapter, they 
support neurons in many ways, all of which are essential for repair and regeneration. 
Disturbances in astrocytic functions are implicated in neurodegenerative diseases 
pathogenesis, therefore, modulation of astrocyte functioning may prove to be an efficient 
therapeutic strategy in many chronic CNS disorders.  
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